HISTORY

A 35 YEAR JOURNEY WITH A RELENTLESS FOCUS ON SCIENCE

Our commitment to patients extends well beyond our labs. We are proud to support the communities we serve, to embrace a culture and business model of patients over profits and to hold the highest ethical standards when it comes to patient well-being.

Jump to year: 2023 2022 2021 2020

Regeneron is founded by Leonard S. Schleifer, MD, PhD, a young neurologist and assistant professor at Cornell University Medical College

1988

Len Schleifer describes how Regeneron raised its first $1 million

Len Schleifer explains how Regeneron got its name

George D. Yancopoulos, MD, PhD, a highly regarded young molecular immunologist at Columbia University, joins Regeneron

1989

Len and George reflect on their long partnership

Science publishes our first paper, which becomes the most highly cited neurobiology paper of the year

1990

We announce a collaboration to develop neurotrophic factors

REGN stock begins trading publicly on the NASDAQ; the initial public offering (IPO) raises $91.6 million

1991

Clinical development of our first investigational drug, a neurotrophic

1992

manufacturing facility in Rensselaer, NY, years before having an FDA-approved medicine

Industry legend P. Roy Vagelos, MD becomes chairman of the board

Dr. Vagelos, another businessman-scientist who had previously led Merck's R&D division, encourages us to focus on research on disease settings where the biological profile can be fully characterized and the clinical benefit evaluated more quickly

1995

1997

The Phase 3 trial of our first neurotrophic factor does not achieve its primary endpoint, and though the team is disappointed, we regroup to focus on new therapeutic solutions

George Yancopoulos, MD, PhD, becomes the decade's 11th most highly cited scientist in the world

1999

2000

Our investigational medicine rilonacept begins clinical exploration

Our first paper on *VelociGene*® is published, introducing the world to our proprietary *Veloci* technologies

We become one of the original sponsors of the Westchester Science & Engineering Fair (WESEF) to support and reward scientific excellence in promising high school students

2003

2004

Our investigational medicine aflibercept begins clinical development

Sarilumab, our first fully human antibody, enters clinical development

A collaboration with Bayer HealthCare focuses on developing aflibercept outside the U.S.

2006

2007

VELOCIMMUNE®

A collaboration with Sanofi focuses on developing fully human antibodies using our *VelocImmune*® technology platform

Arcalyst® (rilonacept) Injection for Subcutaneous Use

collaboration with Sanofi

Our investigational medicine alirocumab begins clinical development

2009

We hire our 1,000th employee and move into new buildings on our Tarrytown campus

*In 2021, Kiniksa assumed U.S. commercial rights to ARCALYST for all approved indications

We begin sponsorship of the BioBus, a mobile laboratory, to drive hands-on science education in underserved school districts

2010

EYLEA® (aflibercept) Injection For Intravitreal Injection

The FDA approves EYLEA® (aflibercept) Injection for its first indication

2011

Our President and CEO, Leonard S. Schleifer, is named Ernst & Young's 2011 New York Entrepreneur Of The Year®

The *Science* Top Employer survey names us the #1 employer in the global biopharmaceutical industry

Scrip Intelligence names us Biotech Company of the Year

2012

We announce the first recipients of our annual Regeneron Prize for Creative Innovation

Our European business office opens in Dublin, Ireland

Scrip Intelligence names Len and George as the "Management Team of the Year"

2013

REGENERON GENETICS CENTER

The Regeneron Genetics Center®, a new human genetics initiative, officially launches

We initiate the STEM Teaching Fellowship, a joint effort with the STEM Leadership Center, to develop a highly trained science teacher community, and Sci2Med Academy in collaboration with Yonkers Partners in Education to broaden career horizons for students who are underrepresented in the science fields. Learn more about our initiatives

We begin building our first ex-U.S. IOPS site in Limerick, Ireland

2014

Praluent® (alirocumab) Injection

The FDA approves PRALUENT® (alirocumab) Injection our fourth FDA-approved medicine and first FDA-approved fully human monoclonal antibody

We launch a major new immuno-oncology collaboration with Sanofi

2015

We are named as the new title sponsor for the Science Talent Search (just the third in the prestigious competition's 75-year history)

2016

DUPIXENT® (dupilumab) Injection

The FDA approves DUPIXENT® (dupilumab) Injection, our fifth FDA-approved medicine

2017

KEVZARA® (sarilumab) injection

DUPIXENT (dupilumab) Injection

The FDA approves a new indication for DUPIXENT® (dupilumab) Injection

LIBTAYO (cemiplimab-rwlc)

The FDA approves Libtayo® (cemiplimab-rwlc) Injection, our seventh FDA-approved medicine

2018

approved medicine and second fully human monoclonal antibody

Recognized on the Civic 50 list of most community-minded companies in the United States

REGENERON DNA LEARNING CENTER

REGENERON ISEF

Regeneron and Cold Spring Harbor Laboratory unveil new dedicated laboratories for student science education. Society for Science announces Regeneron as new sponsor of the International Science and Engineering Fair

2019

The FDA and European Commission approves new indications for EYLEA® (aflibercept) injection, DUPIXENT® (dupilumab) injection, Libtayo® (cemiplimab) injection and PRALUENT® (alirocumab) injection

Regeneron debuts on the prestigious Dow Jones Sustainability World Index of Most Sustainable Companies

DUPIXENT (dupilumab) Injection

The FDA approves an expanded indication for DUPIXENT® (dupilumab) injection

Inmazeb (atoltivimab, maftivimab, and odesivimab – ebgn) Injection

The FDA approves Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn)

Regeneron discovers and develops novel COVID-19 antibody cocktail in record time; FDA authorizes for emergency use

Regeneron named *Science* magazine's #1 biopharma company for the seventh time

2020

The FDA approves new indications for Libtayo® (cemiplimab-rwlc) injection and DUPIXENT® (dupilumab) injection; European Commission approves a new indication for Libtayo® (cemiplimab) injection

The European Commission authorizes Regeneron's COVID-19 antibody cocktail

Regeneron and Intellia announce first-ever clinical data supporting the safety and efficacy of *in vivo* CRISPR genome editing

Intellia THERAPEUTICS

Regeneron Genetics Center discovers *GPR75* gene mutations that protect against obesity

RGC Regeneron Genetics Center

2021

DUPIXENT (dupilumab) Injection

The FDA and European Commission approve new indications for DUPIXENT® (dupilumab) injection

LIBTAYO (cemiplimab-rwlc)

Regeneron takes full ownership of Libtayo® (cemiplimab) injection, with exclusive worldwide development, commercialization and manufacturing rights

The FDA approved Libtayo in first-line NSCLC in combination with chemotherapy in the fourth quarter of 2022

CHECKMATE PHARMACEUTICALS

Regeneron acquires Checkmate

2022

Inmazeb®
(atoltivimab, maftivimab, and odesivimab – ebgn)
Injection

Regeneron awarded the 2022 Prix Galien USA Best Biotechnology Product for Inmazeb®

M.D. retires as board chair

Drs. Leonard S. Schleifer and George D. Yancopoulos become co-chairs of the board

2023

Veopoz™
(pozelimab-bbfg)
Injection

The FDA approves Veopoz™ (pozelimab-bbfg), our tenth FDA-approved medicine

EYLEA® HD
(aflibercept) Injection 8 mg

The FDA approves EYLEA® HD (aflibercept) Injection 8 mg, our eleventh FDA-approved medicine

There may be no other thing you can do that is more rewarding than to really move the human condition forward

George D. Yancopoulos, MD, PhD

Board Co-Chair, President and Chief Scientific Officer